Home >  News >  Industry >  Pharma News >  Bayer loses another...

Bayer loses another appeal against Roundup cancer verdict

By - Ruchika Sharma
Published On 2021-08-11 07:25 GMT   |   Update On 2021-08-11 07:25 GMT
Advertisement

San Francisco: German pharmaceutical and chemical giant Bayer on Monday lost another appeal against a verdict that found its Roundup weedkiller causes cancer, the latest setback in its bid to end thousands of lawsuits over the product.

An appeals court in San Francisco upheld the 2019 ruling in favor of a couple who claimed they got non-Hodgkin's lymphoma after using Roundup for years.
The court also upheld a judge's decision to reduce the jury's compensation award to Alva and Alberta Pilliod from $2 billion to $86.7 million.
Bayer has been plagued by problems since it bought Monsanto, which owns Roundup, in 2018 for $63 billion and inherited its legal woes.
The German firm says it has not committed any wrongdoing, and maintains that scientific studies and regulatory approvals show Roundup's main ingredient glyphosate is safe.
Glyphosate is nonetheless classified as a "probable carcinogen" by the International Agency for Research on Cancer at the World Health Organization (WHO).
Advertisement
In the latest ruling, the appeals court said Monsanto displayed an "intransigent unwillingness to inform the public about the carcinogenic dangers of a product it made abundantly available at hardware stores and garden shops across the country."
"Monsanto knew that studies supporting the safety of Roundup were invalid when the Pilliods began spraying Roundup in their yards, wearing no gloves or protective gear, spurred on by television commercials."
"We respectfully disagree with the Court's ruling as the verdict is not supported by the evidence at trial or the law," a Bayer spokesperson said. "Monsanto will consider its legal options in this case."
"We continue to stand strongly behind the safety of Roundup, a position supported by four decades of extensive science and the assessments of leading health regulators worldwide that support its safe use."
Bayer has set aside more than $15 billion to deal with a wave of US lawsuits linked to the weedkiller.
After allotting its latest tranche of $4.5 billion for potential costs, the German company posted huge losses for its second quarter last week.
In February, it said it had settled some 90,000 cases.
In May, a San Francisco court upheld a damages award of $25 million against Bayer and in favor of California resident Edwin Hardeman.
Bayer has said it will petition the US Supreme Court to review the Hardeman case this month.


Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Eris Lifesciences receives ANVISA approval at its Ahmedabad campus

India laying foundations to emerge as global MedTech hub, says Shri Amit Agrawal

Mandatory Excipients Disclosure on Drug Labels from March 2026: Health Ministry

CDSCO Cancels Import Licence of Mediderma Salipeel Products

Declare Cancer a Notifiable Disease, Bring Cancer Drugs Under Price Control: Parliamentary Panel

CDSCO Panel Rejects Phase III Trial of QL2107 Injection Proposed by Syneos Health

Piramal Pharma Solutions, NewAmsterdam Pharma open dedicated oral solid dosage form suite at Piramal Sellersville facility

Rs 92 Cr Drug Factory Busted in Bhopal: DRI Arrests 7, Exposes International Mephedrone Syndicate